Michelle Dalgas Schmiegelow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michelle Dalgas Schmiegelow has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Christian Torp-Pedersen
Copenhagen University Hospital, Steno Diabetes Center Copenhagen Herlev Denmark
10 shared publications - Gunnar Hilmar Gislason
Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte , Hospitalsvej 1, 2900 Hellerup
10 shared publications - Charlotte Andersson
Center for Advanced Heart Disease, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School , Boston, MA
5 shared publications - Thomas Bo Jensen
Novo Nordisk A/S, Søborg, Denmark
5 shared publications Charlotte Andersson
Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark
3 shared publications- Jonas Bjerring Olesen
Department of Cardiology, Copenhagen University Hospital—Herlev and Gentofte , Cardiovascular Research unit 1, Borgmester Ib Juuls Vej 1, Herlev 2730
3 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (3)
Dilatation of the ascending aorta in bicuspid aortic valve patients with and without concomitant aortic coarctation
Background: In bicuspid aortic valve (BAV) aortopathy, concomitant aortic coarctation and bicuspid aortic valve (cBAV) is considered an aggravating risk factor which may indicate earlier prophylactic intervention. This assumption is challenged by recent studies in children or young adults, reporting smaller aortic diameters in cBAV patients compared with those with isolated BAV (iBAV) disease, but these findings should be confirmed in adult patient populations. Aims: To assess the association between aortic coarctation and aortic dilatation in adult BAV patients. Methods and results: In a prospective cohort study, we included 141 cBAV patients and 828 iBAV patients from outpatient clinics. Maximal diameters of the aortic root and tubular ascending aorta were measured on transthoracic echocardiograms. Aortic diameters, significant aortic dilatation at baseline (≥50 mm or Z-score ≥ 4), and annual aortic growth rates were compared between groups taking possible confounders into account. Compared with iBAV patients, cBAV patients had smaller crude and adjusted diameters (adjusted mean difference: −3.27 mm [−4.49 mm; −2.05 mm]) and a lower likelihood of significant aortic dilatation at baseline (adjusted odds ratio [95% confidence interval]: 0.55 [0.30; 1.01], P = .05). We observed no differences in aortic root dimensions or in aortic growth rates between cBAV and iBAV patients. Conclusions: cBAV was associated with less pronounced dilatation of the tubular ascending aorta in adult BAV patients.
- 6 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (3)
Open AccessDilatation of the ascending aorta in bicuspid aortic valve patients with and without concomitant aortic coarctation
Background: In bicuspid aortic valve (BAV) aortopathy, concomitant aortic coarctation and bicuspid aortic valve (cBAV) is considered an aggravating risk factor which may indicate earlier prophylactic intervention. This assumption is challenged by recent studies in children or young adults, reporting smaller aortic diameters in cBAV patients compared with those with isolated BAV (iBAV) disease, but these findings should be confirmed in adult patient populations. Aims: To assess the association between aortic coarctation and aortic dilatation in adult BAV patients. Methods and results: In a prospective cohort study, we included 141 cBAV patients and 828 iBAV patients from outpatient clinics. Maximal diameters of the aortic root and tubular ascending aorta were measured on transthoracic echocardiograms. Aortic diameters, significant aortic dilatation at baseline (≥50 mm or Z-score ≥ 4), and annual aortic growth rates were compared between groups taking possible confounders into account. Compared with iBAV patients, cBAV patients had smaller crude and adjusted diameters (adjusted mean difference: −3.27 mm [−4.49 mm; −2.05 mm]) and a lower likelihood of significant aortic dilatation at baseline (adjusted odds ratio [95% confidence interval]: 0.55 [0.30; 1.01], P = .05). We observed no differences in aortic root dimensions or in aortic growth rates between cBAV and iBAV patients. Conclusions: cBAV was associated with less pronounced dilatation of the tubular ascending aorta in adult BAV patients.
- Open Access
- 19 August 2025
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 115 (7) , 1166-1177
Valve morphology and timing of surgery in bicuspid aortic valve disease
Background: The anatomy of bicuspid aortic valves (BAV) varies considerably and is broadly classified into two main types: two-sinus and fused BAV. Possible prognostic implications of these two main types remain unclear. This study aimed to assess potential associations between BAV morphology and the timing of surgery of the aortic valve or ascending aorta. Methods: A multi-center cohort study including 1004 adult outpatients with BAV. BAV morphology was classified as either two-sinus or fused type. The primary outcome was a composite of surgical or endovascular intervention on the aortic valve or ascending aorta. The effect of morphology on the primary outcome was investigated using delayed-entry cause-specific Cox regression models using age as timescale. Results: A total of 835 patients with fused BAV and 169 with two-sinus BAV were followed for 2044 person-years. Two-sinus BAV patients were younger (median age 47.2 vs. 53.6 years, p = 0.0002) with a higher prevalence of aortic coarctation (24% vs. 12%, p = 0.0003). The incidence rate of surgery was 9.3 per 100 person-years in fused BAV patients and 10.7 per 100 person-years in two-sinus BAV patients (difference [95%CI]: 1.42 [− 2.3, 5.1] per 100 person-years). Two-sinus morphology was associated with a higher age-related hazard of surgery compared to fused BAV (HR [95%CI]: 1.46 [1.02, 2.09]), a finding that remained significant after adjusting for sex. Conclusion: Two-sinus BAV morphology was associated with a significantly higher age-related likelihood of requiring surgery on the aortic valve or ascending aorta.
- 19 August 2025
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 115 (7) , 1166-1177
Open AccessValve morphology and timing of surgery in bicuspid aortic valve disease
Background: The anatomy of bicuspid aortic valves (BAV) varies considerably and is broadly classified into two main types: two-sinus and fused BAV. Possible prognostic implications of these two main types remain unclear. This study aimed to assess potential associations between BAV morphology and the timing of surgery of the aortic valve or ascending aorta. Methods: A multi-center cohort study including 1004 adult outpatients with BAV. BAV morphology was classified as either two-sinus or fused type. The primary outcome was a composite of surgical or endovascular intervention on the aortic valve or ascending aorta. The effect of morphology on the primary outcome was investigated using delayed-entry cause-specific Cox regression models using age as timescale. Results: A total of 835 patients with fused BAV and 169 with two-sinus BAV were followed for 2044 person-years. Two-sinus BAV patients were younger (median age 47.2 vs. 53.6 years, p = 0.0002) with a higher prevalence of aortic coarctation (24% vs. 12%, p = 0.0003). The incidence rate of surgery was 9.3 per 100 person-years in fused BAV patients and 10.7 per 100 person-years in two-sinus BAV patients (difference [95%CI]: 1.42 [− 2.3, 5.1] per 100 person-years). Two-sinus morphology was associated with a higher age-related hazard of surgery compared to fused BAV (HR [95%CI]: 1.46 [1.02, 2.09]), a finding that remained significant after adjusting for sex. Conclusion: Two-sinus BAV morphology was associated with a significantly higher age-related likelihood of requiring surgery on the aortic valve or ascending aorta.
- 19 August 2021
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 61 (3) , 614-622
Reintervention rates following bioprosthetic surgical aortic valve replacement—a Danish Nationwide Cohort Study
: OBJECTIVES: Updated European guidelines recommend annual echocardiographic evaluation after bioprosthetic surgical aortic valve replacement (bio-SAVR). Given the increased demand on health care resources, only clinically relevant controls can be prioritized. We therefore aimed to explore reintervention rates following bio-SAVR. METHODS: From the nationwide Danish Register of Surgical Procedures, we identified all patients ≥40 years with isolated bio-SAVR ± concomitant coronary artery bypass graft surgery (CABG) during 2000–2016. In 90-day reintervention-free survivors, we assessed aortic valve reintervention rates (primary outcome) and all-cause mortality rates (secondary outcome) at 1, 3 and 5 years with total follow-up until 31 December 2017 and further estimated annual theoretical echocardiographic control visits. RESULTS: In 10 518 patients with bio-SAVR (+CABG 39.7%), we observed low reintervention rates at 1, 3 and 5 years, but with high rates of all-cause mortality; i.e. 5-year reintervention rate of 3.7/1000 person-years (≤1.5%) and 5-year mortality rate of 21.7/1000 person-years. Accounting for the competing risk of death, 5-year rates were inversely related to age group and remained relatively low across all age categories but increased gradually in the long term. A significant proportion of reinterventions were presumed due to infectious endocarditis (48% at 3 years, 37% at 5 years). With annual transthoracic echocardiography, the theoretical ratio of echocardiographies per reintervention in the first 5 years was 248, and 425 when endocarditis events were excluded. CONCLUSION: Reintervention rates within the first 5 years following bio-SAVR were relatively rare, and with a substantial number due to endocarditis.
- 19 August 2021
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 61 (3) , 614-622
Reintervention rates following bioprosthetic surgical aortic valve replacement—a Danish Nationwide Cohort Study
: OBJECTIVES: Updated European guidelines recommend annual echocardiographic evaluation after bioprosthetic surgical aortic valve replacement (bio-SAVR). Given the increased demand on health care resources, only clinically relevant controls can be prioritized. We therefore aimed to explore reintervention rates following bio-SAVR. METHODS: From the nationwide Danish Register of Surgical Procedures, we identified all patients ≥40 years with isolated bio-SAVR ± concomitant coronary artery bypass graft surgery (CABG) during 2000–2016. In 90-day reintervention-free survivors, we assessed aortic valve reintervention rates (primary outcome) and all-cause mortality rates (secondary outcome) at 1, 3 and 5 years with total follow-up until 31 December 2017 and further estimated annual theoretical echocardiographic control visits. RESULTS: In 10 518 patients with bio-SAVR (+CABG 39.7%), we observed low reintervention rates at 1, 3 and 5 years, but with high rates of all-cause mortality; i.e. 5-year reintervention rate of 3.7/1000 person-years (≤1.5%) and 5-year mortality rate of 21.7/1000 person-years. Accounting for the competing risk of death, 5-year rates were inversely related to age group and remained relatively low across all age categories but increased gradually in the long term. A significant proportion of reinterventions were presumed due to infectious endocarditis (48% at 3 years, 37% at 5 years). With annual transthoracic echocardiography, the theoretical ratio of echocardiographies per reintervention in the first 5 years was 248, and 425 when endocarditis events were excluded. CONCLUSION: Reintervention rates within the first 5 years following bio-SAVR were relatively rare, and with a substantial number due to endocarditis.
- Open Access
- 6 July 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (13) , e020395
Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low‐Risk Population With Type 2 Diabetes Mellitus
Background: We examined whether primary prevention with statins and high adherence to statins reduce the associated risk of cardiovascular events or death in a low‐risk population with type 2 diabetes mellitus (T2D). Methods and Results: Using Danish nationwide registers, we included patients with new‐onset T2D, aged 40 to 89 years, between 2005 and 2011, who were alive 18 months following the T2D diagnosis (index date). In patients who purchased statins within 6 months following T2D diagnosis, we calculated the proportion of days covered (PDC) within 1 year after the initial 6‐month period. We studied the combined end point of myocardial infarction, stroke, or all‐cause mortality, whichever came first, with Cox regression. Reported were standardized 5‐year risk differences for fixed comorbidity distribution according to statin treatment history, stratified by sex and age. Among 77 170 patients, 42 975 (56%) were treated with statins, of whom 31 061 (72%) had a PDC ≥80%. In men aged 70 to 79 years who were treated with statins, the standardized 5‐year risk was 22.9% (95% CI, 21.5%–24.3%), whereas the risk was 29.1% (95% CI, 27.4%–30.7%) in men not treated, resulting in a significant risk reduction of 6.2% (95% CI, 4.0%–8.4%), P <0.0001. The risk reduction associated with statins increased with advancing age group (women: age 40–49 years, 0.0% [95% CI, −1.0% to 1.0%]; age 80–89 years, 10.8% [95% CI, 7.2%–14.4%]). Standardizing to all patients treated with statins, PDC <80% was associated with increased risk difference (reference PDC ≥80%; PDC <20%, 4.2% [95% CI, 2.9%–5.6%]). Conclusions: This study supports the use of statins as primary prevention against cardiovascular diseases or death in 18‐month surviving low‐risk patients with T2D, with the highest effect in the elderly and adherent patients.
- 6 July 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (13) , e020395
Open AccessCompliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low‐Risk Population With Type 2 Diabetes Mellitus
Background: We examined whether primary prevention with statins and high adherence to statins reduce the associated risk of cardiovascular events or death in a low‐risk population with type 2 diabetes mellitus (T2D). Methods and Results: Using Danish nationwide registers, we included patients with new‐onset T2D, aged 40 to 89 years, between 2005 and 2011, who were alive 18 months following the T2D diagnosis (index date). In patients who purchased statins within 6 months following T2D diagnosis, we calculated the proportion of days covered (PDC) within 1 year after the initial 6‐month period. We studied the combined end point of myocardial infarction, stroke, or all‐cause mortality, whichever came first, with Cox regression. Reported were standardized 5‐year risk differences for fixed comorbidity distribution according to statin treatment history, stratified by sex and age. Among 77 170 patients, 42 975 (56%) were treated with statins, of whom 31 061 (72%) had a PDC ≥80%. In men aged 70 to 79 years who were treated with statins, the standardized 5‐year risk was 22.9% (95% CI, 21.5%–24.3%), whereas the risk was 29.1% (95% CI, 27.4%–30.7%) in men not treated, resulting in a significant risk reduction of 6.2% (95% CI, 4.0%–8.4%), P <0.0001. The risk reduction associated with statins increased with advancing age group (women: age 40–49 years, 0.0% [95% CI, −1.0% to 1.0%]; age 80–89 years, 10.8% [95% CI, 7.2%–14.4%]). Standardizing to all patients treated with statins, PDC <80% was associated with increased risk difference (reference PDC ≥80%; PDC <20%, 4.2% [95% CI, 2.9%–5.6%]). Conclusions: This study supports the use of statins as primary prevention against cardiovascular diseases or death in 18‐month surviving low‐risk patients with T2D, with the highest effect in the elderly and adherent patients.
- Open Access
- 20 December 2019
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (13) , 1346-1353
Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?
Aims: To investigate whether diabetes confers higher relative rates of cardiovascular events in women compared with men using contemporary data, and whether these sex-differences depend on age. Methods and results: All Danish residents aged 40–89 years without a history major adverse cardiovascular events, including heart failure, as of 1 January 2012 until 31 December 2016 were categorized by diabetes-status and characterized by individual-level linkage of Danish nationwide administrative registers. We used Poisson regression to calculate overall and age-dependent incidence rates, incidence rate ratios, and women-to-men ratios for myocardial infarction, heart failure, ischaemic stroke, or cardiovascular death (MACE-HF). Among 218 549 (46% women) individuals with diabetes, the absolute rate of MACE-HF was higher in men than in women (24.9 vs. 19.9 per 1000 person-years). Corresponding absolute rates in men and women without diabetes were 10.1 vs. 7.0 per 1000 person-years. Comparing individuals with and without diabetes, women had higher relative rates of MACE-HF than men [2.8 (confidence interval, CI 2.9–2.9) in women vs. 2.5 (CI 2.4–2.5) in men] with a women-to-men ratio of 1.15 (CI 1.11–1.19, P < 0.001). The relative rates of MACE-HF were highest in the youngest and decreased with advancing age for both men and women, but the relative rates were higher in women across all ages, with the highest women-to-men ratio between age 50 and 60 years. Conclusion: Although men have higher absolute rates of cardiovascular complications, the relative rates of cardiovascular complications associated with diabetes are higher in women than in men across all ages in the modern era.
- 20 December 2019
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (13) , 1346-1353
Open AccessDoes type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?
Aims: To investigate whether diabetes confers higher relative rates of cardiovascular events in women compared with men using contemporary data, and whether these sex-differences depend on age. Methods and results: All Danish residents aged 40–89 years without a history major adverse cardiovascular events, including heart failure, as of 1 January 2012 until 31 December 2016 were categorized by diabetes-status and characterized by individual-level linkage of Danish nationwide administrative registers. We used Poisson regression to calculate overall and age-dependent incidence rates, incidence rate ratios, and women-to-men ratios for myocardial infarction, heart failure, ischaemic stroke, or cardiovascular death (MACE-HF). Among 218 549 (46% women) individuals with diabetes, the absolute rate of MACE-HF was higher in men than in women (24.9 vs. 19.9 per 1000 person-years). Corresponding absolute rates in men and women without diabetes were 10.1 vs. 7.0 per 1000 person-years. Comparing individuals with and without diabetes, women had higher relative rates of MACE-HF than men [2.8 (confidence interval, CI 2.9–2.9) in women vs. 2.5 (CI 2.4–2.5) in men] with a women-to-men ratio of 1.15 (CI 1.11–1.19, P < 0.001). The relative rates of MACE-HF were highest in the youngest and decreased with advancing age for both men and women, but the relative rates were higher in women across all ages, with the highest women-to-men ratio between age 50 and 60 years. Conclusion: Although men have higher absolute rates of cardiovascular complications, the relative rates of cardiovascular complications associated with diabetes are higher in women than in men across all ages in the modern era.
- Open Access
- 22 October 2018
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 18 (1) , 1-9
Incidence of new onset cancer in patients with a myocardial infarction – a nationwide cohort study
Few studies have suggested that patients with myocardial infarction (MI) may be at increased risk of cancer, but further large register-based studies are needed to evaluate this subject. The aim of this study was to assess the incident rates of cancer and death by history of MI, and whether an MI is independently associated with cancer in a large cohort study. All Danish residents aged 30–99 in 1996 without prior cancer or MI were included and were followed until 2012. Patients were grouped according to incident MI during follow-up. Incidence rates (IR) of cancer and death in individuals with and without MI and incidence rate ratios (IRR, using multivariable Poisson regression analyses) of cancer associated with an MI were calculated. Of 2,871,168 individuals, 122,275 developed an MI during follow-up, 11,375 subsequently developed cancer (9.3%, IR 19.1/1000 person-years) and 65,225 died (53.3%, IR 106.0/1000 person-years). In the reference population, 372,397 developed cancer (13.0%, IR 9.3/1000 person-years) and 753,767 died (26.3%, IR 18.2/1000 person-years). Compared to the reference population, higher IRs of cancer and death were observed in all age groups (30–54, 55–69 and 70–99 years) and time since an MI (0–1, 1–5 and 5–17 years) in the MI population. MI was associated with an increased risk of overall cancer (IRR 1.14, 95% CI 1.10–1.19) after adjusting for age, sex and calendar year, also when additionally adjusting for chronic obstructive pulmonary disease, hypertension, dyslipidemia, diabetes and socioeconomic status (IRR 1.08, 95% CI 1.03–1.13), but not after further adjustment for the first 6 months post-MI (IRR 1.00, 95% CI 0.96–1.05). Patients after an MI have increased incidence of cancer, which may be explained by mutual risk, occult cancers and increased surveillance. Focus on risk factor management to reduce cancer and MI is warranted.
- 22 October 2018
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 18 (1) , 1-9
Open AccessIncidence of new onset cancer in patients with a myocardial infarction – a nationwide cohort study
Few studies have suggested that patients with myocardial infarction (MI) may be at increased risk of cancer, but further large register-based studies are needed to evaluate this subject. The aim of this study was to assess the incident rates of cancer and death by history of MI, and whether an MI is independently associated with cancer in a large cohort study. All Danish residents aged 30–99 in 1996 without prior cancer or MI were included and were followed until 2012. Patients were grouped according to incident MI during follow-up. Incidence rates (IR) of cancer and death in individuals with and without MI and incidence rate ratios (IRR, using multivariable Poisson regression analyses) of cancer associated with an MI were calculated. Of 2,871,168 individuals, 122,275 developed an MI during follow-up, 11,375 subsequently developed cancer (9.3%, IR 19.1/1000 person-years) and 65,225 died (53.3%, IR 106.0/1000 person-years). In the reference population, 372,397 developed cancer (13.0%, IR 9.3/1000 person-years) and 753,767 died (26.3%, IR 18.2/1000 person-years). Compared to the reference population, higher IRs of cancer and death were observed in all age groups (30–54, 55–69 and 70–99 years) and time since an MI (0–1, 1–5 and 5–17 years) in the MI population. MI was associated with an increased risk of overall cancer (IRR 1.14, 95% CI 1.10–1.19) after adjusting for age, sex and calendar year, also when additionally adjusting for chronic obstructive pulmonary disease, hypertension, dyslipidemia, diabetes and socioeconomic status (IRR 1.08, 95% CI 1.03–1.13), but not after further adjustment for the first 6 months post-MI (IRR 1.00, 95% CI 0.96–1.05). Patients after an MI have increased incidence of cancer, which may be explained by mutual risk, occult cancers and increased surveillance. Focus on risk factor management to reduce cancer and MI is warranted.
- Open Access
- 22 February 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 133
Associations between metabolic disorders and risk of cancer in Danish men and women – a nationwide cohort study
The prevalence of metabolic disorders is increasing and has been suggested to increase cancer risk, but the relation between metabolic disorders and risk of cancer is unclear, especially in young adults. We investigated the associations between diabetes, hypertension, and hypercholesterolemia on risk of all-site as well as site-specific cancers. We consecutively included men and women from nationwide Danish registries 1996–2011, if age 20–89 and without cancer prior to date of entry. We followed them throughout 2012. Metabolic disorders were defined using discharge diagnosis codes and claimed prescriptions. We used time-dependent sex-stratified Poisson regression models adjusted for age and calendar year to assess associations between metabolic disorders, and risk of all-site and site-specific cancer (no metabolic disorders as reference). Over a mean follow-up of 12.6 (±5.7 standard deviations [SD]) years, 4,826,142 individuals (50.2 % women) with a mean age of 41.4 (±18.9 SD) years had 423,942 incident cancers. Incidence rate ratios (IRRs) of all-site cancer in patients with diabetes or hypertension were highest immediately following diagnosis of metabolic disorder. In women, cancer risk associated with diabetes continued to decline albeit remained significant (IRRs of 1.18–1.22 in years 1–8 following diagnosis). For diabetes in men, and hypertension, IRRs stabilized and remained significantly increased after about one year with IRRs of 1.10-1.13 in men for diabetes, and 1.07–1.14 for hypertension in both sexes. Conversely, no association was observed between hypercholesterolemia (treatment with statins) and cancer risk. The association between hypertension and cancer risk was strongest in young adults aged 20–34 and decreased with advancing age. Diabetes and hypertension were associated with increased risk of all-site cancer.
- 22 February 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 133
Open AccessAssociations between metabolic disorders and risk of cancer in Danish men and women – a nationwide cohort study
The prevalence of metabolic disorders is increasing and has been suggested to increase cancer risk, but the relation between metabolic disorders and risk of cancer is unclear, especially in young adults. We investigated the associations between diabetes, hypertension, and hypercholesterolemia on risk of all-site as well as site-specific cancers. We consecutively included men and women from nationwide Danish registries 1996–2011, if age 20–89 and without cancer prior to date of entry. We followed them throughout 2012. Metabolic disorders were defined using discharge diagnosis codes and claimed prescriptions. We used time-dependent sex-stratified Poisson regression models adjusted for age and calendar year to assess associations between metabolic disorders, and risk of all-site and site-specific cancer (no metabolic disorders as reference). Over a mean follow-up of 12.6 (±5.7 standard deviations [SD]) years, 4,826,142 individuals (50.2 % women) with a mean age of 41.4 (±18.9 SD) years had 423,942 incident cancers. Incidence rate ratios (IRRs) of all-site cancer in patients with diabetes or hypertension were highest immediately following diagnosis of metabolic disorder. In women, cancer risk associated with diabetes continued to decline albeit remained significant (IRRs of 1.18–1.22 in years 1–8 following diagnosis). For diabetes in men, and hypertension, IRRs stabilized and remained significantly increased after about one year with IRRs of 1.10-1.13 in men for diabetes, and 1.07–1.14 for hypertension in both sexes. Conversely, no association was observed between hypercholesterolemia (treatment with statins) and cancer risk. The association between hypertension and cancer risk was strongest in young adults aged 20–34 and decreased with advancing age. Diabetes and hypertension were associated with increased risk of all-site cancer.
- Open Access
- 1 May 2015
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 4 (5)
Race and Ethnicity, Obesity, Metabolic Health, and Risk of Cardiovascular Disease in Postmenopausal Women
Background: It is unclear whether obesity unaccompanied by metabolic abnormalities is associated with increased cardiovascular disease risk across racial and ethnic subgroups. Methods and Results: We identified 14 364 postmenopausal women from the Women's Health Initiative who had data on fasting serum lipids and serum glucose and no history of cardiovascular disease or diabetes at baseline. We categorized women by body mass index ( in kg/m 2 ) as normal weight ( body mass index 18.5 to P =0.05). Obese black women without metabolic syndrome had higher adjusted risk ( HR 1.95) than obese white women ( HR 1.07; interaction P =0.02). Among women with only 2 metabolic abnormalities, cardiovascular risk was increased in black women who were overweight ( HR 1.77) or obese ( HR 2.17) but not in white women who were overweight ( HR 0.98) or obese ( HR 1.06). Overweight and obese women with ≤1 metabolic abnormality did not have increased cardiovascular risk, regardless of race or ethnicity. Conclusions: Metabolic abnormalities appeared to convey more cardiovascular risk among black women.
- 1 May 2015
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 4 (5)
Open AccessRace and Ethnicity, Obesity, Metabolic Health, and Risk of Cardiovascular Disease in Postmenopausal Women
Background: It is unclear whether obesity unaccompanied by metabolic abnormalities is associated with increased cardiovascular disease risk across racial and ethnic subgroups. Methods and Results: We identified 14 364 postmenopausal women from the Women's Health Initiative who had data on fasting serum lipids and serum glucose and no history of cardiovascular disease or diabetes at baseline. We categorized women by body mass index ( in kg/m 2 ) as normal weight ( body mass index 18.5 to P =0.05). Obese black women without metabolic syndrome had higher adjusted risk ( HR 1.95) than obese white women ( HR 1.07; interaction P =0.02). Among women with only 2 metabolic abnormalities, cardiovascular risk was increased in black women who were overweight ( HR 1.77) or obese ( HR 2.17) but not in white women who were overweight ( HR 0.98) or obese ( HR 1.06). Overweight and obese women with ≤1 metabolic abnormality did not have increased cardiovascular risk, regardless of race or ethnicity. Conclusions: Metabolic abnormalities appeared to convey more cardiovascular risk among black women.
- 1 May 2015
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 8 (3) , 309-316
Insulin Resistance and Risk of Cardiovascular Disease in Postmenopausal Women
Background—: Insulin resistance is associated with diabetes mellitus, but it is uncertain whether it improves cardiovascular disease (CVD) risk prediction beyond traditional cardiovascular risk factors. Methods and Results—: We identified 15 288 women from the Women’s Health Initiative Biomarkers studies with no history of CVD, atrial fibrillation, or diabetes mellitus at baseline (1993–1998). We assessed the prognostic value of adding fasting serum insulin, HOMA-IR (homeostasis model assessment–insulin resistance), serum-triglyceride-to-serum-high-density lipoprotein-cholesterol ratio TG/HDL-C, or impaired fasting glucose (serum glucose ≥110 mg/dL) to traditional risk factors in separate Cox multivariable analyses and assessed risk discrimination and reclassification. The study end point was major CVD events (nonfatal and fatal coronary heart disease and ischemic stroke) within 10 years, which occurred in 894 (5.8%) women. Insulin resistance was associated with CVD risk after adjusting for age and race/ethnicity with hazard ratios (95% confidence interval [CI]) per doubling in insulin of 1.21 (CI, 1.12–1.31), in HOMA-IR of 1.19 (CI, 1.11–1.28), in TG/HDL-C of 1.35 (CI, 1.26–1.45), and for impaired fasting glucose of 1.31 (CI, 1.05–1.64). Although insulin, HOMA-IR, and TG/HDL-C remained associated with increased CVD risk after adjusting for most CVD risk factors, none remained significant after adjusting for HDL-C: hazard ratios for insulin, 1.06 (CI, 0.98–1.16); for HOMA-IR, 1.06 (CI, 0.98–1.15); for TG/HDL-C, 1.11 (CI, 0.99–1.25); and for glucose, 1.20 (CI, 0.96–1.50). Insulin resistance measures did not improve CVD risk discrimination and reclassification. Conclusions—: Measures of insulin resistance were no longer associated with CVD risk after adjustment for high-density lipoprotein-cholesterol and did not provide independent prognostic information in postmenopausal women without diabetes mellitus. Clinical Trial Registration Information—: URL: http://www.clinicaltrial.gov . Unique identifier: NCT00000611.
- 1 May 2015
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 8 (3) , 309-316
Insulin Resistance and Risk of Cardiovascular Disease in Postmenopausal Women
Background—: Insulin resistance is associated with diabetes mellitus, but it is uncertain whether it improves cardiovascular disease (CVD) risk prediction beyond traditional cardiovascular risk factors. Methods and Results—: We identified 15 288 women from the Women’s Health Initiative Biomarkers studies with no history of CVD, atrial fibrillation, or diabetes mellitus at baseline (1993–1998). We assessed the prognostic value of adding fasting serum insulin, HOMA-IR (homeostasis model assessment–insulin resistance), serum-triglyceride-to-serum-high-density lipoprotein-cholesterol ratio TG/HDL-C, or impaired fasting glucose (serum glucose ≥110 mg/dL) to traditional risk factors in separate Cox multivariable analyses and assessed risk discrimination and reclassification. The study end point was major CVD events (nonfatal and fatal coronary heart disease and ischemic stroke) within 10 years, which occurred in 894 (5.8%) women. Insulin resistance was associated with CVD risk after adjusting for age and race/ethnicity with hazard ratios (95% confidence interval [CI]) per doubling in insulin of 1.21 (CI, 1.12–1.31), in HOMA-IR of 1.19 (CI, 1.11–1.28), in TG/HDL-C of 1.35 (CI, 1.26–1.45), and for impaired fasting glucose of 1.31 (CI, 1.05–1.64). Although insulin, HOMA-IR, and TG/HDL-C remained associated with increased CVD risk after adjusting for most CVD risk factors, none remained significant after adjusting for HDL-C: hazard ratios for insulin, 1.06 (CI, 0.98–1.16); for HOMA-IR, 1.06 (CI, 0.98–1.15); for TG/HDL-C, 1.11 (CI, 0.99–1.25); and for glucose, 1.20 (CI, 0.96–1.50). Insulin resistance measures did not improve CVD risk discrimination and reclassification. Conclusions—: Measures of insulin resistance were no longer associated with CVD risk after adjustment for high-density lipoprotein-cholesterol and did not provide independent prognostic information in postmenopausal women without diabetes mellitus. Clinical Trial Registration Information—: URL: http://www.clinicaltrial.gov . Unique identifier: NCT00000611.
- 15 April 2015
- Published by Wiley in Clinical Obesity
- Vol. 5 (3) , 127-135
Impact of metabolic disorders on the relation between overweight/obesity and incident myocardial infarction and ischaemic stroke in fertile women: a nationwide cohort study
Summary: Aims: Whether overweight is a risk factor for cardiovascular disease in the absence of metabolic disorders remains under debate and is largely unexamined in young women. We evaluated the risk of myocardial infarction and ischaemic stroke in fertile women conditional on time‐dependent presence of metabolic disorders.Materials and methods: From nationwide registers we identified all normal weight (body mass index [BMI] ≥ 18.5 to −2) and overweight (BMI ≥ 25 kg m−2) Danish women giving birth from 2004 to 2009. Using multivariable Poisson regression models adjusted for age, calendar year and smoking, the risk of the composite outcome of myocardial infarction and ischaemic stroke was assessed with metabolic disorders (i.e. hypertensive conditions, abnormal glucose metabolism and/or dyslipidaemia) included as time‐dependent variables.Results: The population comprised 261 489 women with median age of 30.5 years (interquartile range = [27.3, 33.8] ). Median follow‐up was 5.6 years (interquartile range = [4.0, 6.8] ). Compared with normal weight women without metabolic disorders (with an incidence rate [IR] of 17.0 [95% confidence interval {CI} = 14.5–20.0] events per 100 000 person‐years), overweight women without metabolic disorders had no significantly increased risk, IR 22.6 (CI = 18.3–27.8), adjusted incidence rate ratio (IRR), 1.26 (CI = 0.97–1.65). For women with metabolic disorders, IR was 30.2 (CI = 18.8–48.6) and adjusted IRR 1.77 (CI = 1.07–2.93) in normal weight, while IR was 87.1 (CI = 67.6–112.2) and IRR 4.24 (CI = 5 3.11–5.79) in overweight.Conclusions: The risk of myocardial infarction and ischaemic stroke was more strongly associated with the presence of metabolic disorders than with overweight per se in fertile women. Targeting prevention of metabolic disorders might be beneficial to reduce cardiovascular disease in overweight/obese young women.
- 15 April 2015
- Published by Wiley in Clinical Obesity
- Vol. 5 (3) , 127-135
Impact of metabolic disorders on the relation between overweight/obesity and incident myocardial infarction and ischaemic stroke in fertile women: a nationwide cohort study
Summary: Aims: Whether overweight is a risk factor for cardiovascular disease in the absence of metabolic disorders remains under debate and is largely unexamined in young women. We evaluated the risk of myocardial infarction and ischaemic stroke in fertile women conditional on time‐dependent presence of metabolic disorders.Materials and methods: From nationwide registers we identified all normal weight (body mass index [BMI] ≥ 18.5 to −2) and overweight (BMI ≥ 25 kg m−2) Danish women giving birth from 2004 to 2009. Using multivariable Poisson regression models adjusted for age, calendar year and smoking, the risk of the composite outcome of myocardial infarction and ischaemic stroke was assessed with metabolic disorders (i.e. hypertensive conditions, abnormal glucose metabolism and/or dyslipidaemia) included as time‐dependent variables.Results: The population comprised 261 489 women with median age of 30.5 years (interquartile range = [27.3, 33.8] ). Median follow‐up was 5.6 years (interquartile range = [4.0, 6.8] ). Compared with normal weight women without metabolic disorders (with an incidence rate [IR] of 17.0 [95% confidence interval {CI} = 14.5–20.0] events per 100 000 person‐years), overweight women without metabolic disorders had no significantly increased risk, IR 22.6 (CI = 18.3–27.8), adjusted incidence rate ratio (IRR), 1.26 (CI = 0.97–1.65). For women with metabolic disorders, IR was 30.2 (CI = 18.8–48.6) and adjusted IRR 1.77 (CI = 1.07–2.93) in normal weight, while IR was 87.1 (CI = 67.6–112.2) and IRR 4.24 (CI = 5 3.11–5.79) in overweight.Conclusions: The risk of myocardial infarction and ischaemic stroke was more strongly associated with the presence of metabolic disorders than with overweight per se in fertile women. Targeting prevention of metabolic disorders might be beneficial to reduce cardiovascular disease in overweight/obese young women.